Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients.

Cancer Med · 2020 · PMC7724300 · PMID 33049118

Europe PMC DOI

hedged sentence

0.0598

closest p · 1.2× alpha

0.0598

boldest claim

The sentences

did not reach statistical significancep = 0.05980so close (0.05 < p ≤ 0.1)

The benefit of continuous vs fixed‐duration treatment was seen with a >7‐month improvement in median PFS with Rd continuous vs Rd18 (29.3 vs 21.9 months), although the difference did not reach statistical significance ( p = 0.05980).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.